Preclinical validation of a potent γ-secretase modulator for Alzheimer’s disease prevention
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
A potent γ-secretase modulator (GSM) has been developed to circumvent problems associated with γ-secretase inhibitors (GSIs) and to potentially enable use in primary prevention of early-onset familial Alzheimer’s disease (EOFAD). Unlike GSIs, GSMs do not inhibit γ-secretase activity but rather allosterically modulate γ-secretase, reducing the net production of Aβ42 and to a lesser extent Aβ40, while concomitantly augmenting production of Aβ38 and Aβ37. This GSM demonstrated robust time- and dose-dependent efficacy in acute, subchronic, and chronic studies across multiple species, including primary and secondary prevention studies in a transgenic mouse model. The GSM displayed a >40-fold safety margin in rats based on a comparison of the systemic exposure (AUC) at the no observed adverse effect level (NOAEL) to the 50% effective AUC or AUCeffective, the systemic exposure required for reducing levels of Aβ42 in rat brain by 50%.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








![Figure 9. Efficacy of GSM compound 2 on various Aβ peptide levels in plasma of NHPs. (A) Plasma levels of Aβ38, Aβ40, and Aβ42 in male and female NHPs (n = 4/dose) at 4 h following a single nasogastric dose of 0 mg/kg (vehicle), 10 mg/kg (mean plasma [drug] = 753 ng/ml), 30 mg/kg (mean plasma [drug] = 1,235 ng/ml), 100 mg/kg (mean plasma [drug] = 2,895 ng/ml), or 200 mg/kg (mean plasma [drug] = 2,475 ng/ml). (B) Plasma levels of Aβ38, Aβ40, and Aβ42 in male and female NHPs (n = 4/time point) following a single nasogastric dose (200 mg/kg) on day 1 of the repeat-dosing phase in the DRF toxicokinetic study measured at 0 h (mean plasma [drug] = LLOQ), 1 h (mean plasma [drug] = 109 ng/ml), 2 h (mean plasma [drug] = 460 ng/ml), 4 h (mean plasma [drug] = 2,300 ng/ml), 8 h (mean plasma [drug] = 2,560 ng/ml), or 24 h (mean plasma [drug] = 1,705 ng/ml) after drug or vehicle administration. Aβ38, Aβ40, and Aβ42 peptides were quantitated using Meso Scale Sector 6000 Multiplex assays. Data are expressed as picograms per milliliter. Statistical analysis was performed using GraphPad Prism software, and results are expressed as mean ± SEM. ANOVA was used to detect a significant effect. *, P < 0.05; **, P < 0.01; ***, P < 0.001.](https://figures.cochat.ai/paper-figures/60a7435996c54d4fa835989c1dafa877/preclinical-validation-of-a-potent-secretase-modulator-for-alzheimers-disease-figure-9.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some γ-secretase modulators (GSMs) also exhibited promising safety outcomes in preclinical studies and clinical trials.546–548”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [548]
The cited source says what the claim attributes to it.
In the citing paper
“Allosteric modulators of γ-secretase encourage the production of shorter, less toxic Aβ subtypes, and even potentially minimize effects on Notch and some other substrates. Some γ-secretase modulators (GSMs) also exhibited promising safety outcomes in preclinical studies and clinical trials.546–548”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [548]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain
De Strooper, B., Annaert, W., Cupers, P., Saftig, P., Craessaerts, K., Mumm, J. S., Schroeter, E. H., Schrijvers, V., Wolfe, M. S., Ray, W. J., et al. (1999) · Nature · doi:10.1038/19083 · Cited by 2,100
The Ames Salmonella/microsome mutagenicity assay
Mortelmans, K., & Zeiger, E. (2000) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(00)00064-6 · Cited by 2,098
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Self-citationIwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Emerging diagnostics and therapeutics for Alzheimer disease
Self, W. K., & Holtzman, D. M. (2023) · Nature Medicine · doi:10.1038/s41591-023-02505-2 · Cited by 381
γ-Secretase in Alzheimer’s disease
Hur, J.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00754-8 · Cited by 310
The neuroimmune axis of Alzheimer’s disease
Jorfi, M., Maaser-Hecker, A., & Tanzi, R. E. (2023) · Genome Medicine · doi:10.1186/s13073-023-01155-w · Cited by 292
Self-citationThe case for low-level BACE1 inhibition for the prevention of Alzheimer disease
McDade, E., Voytyuk, I., Aisen, P. S. S., Bateman, R. J., Carrillo, M. C., Strooper, B. D., Haass, C., Reiman, E. M., Sperling, R. A., Tariot, P. N., et al. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00545-1 · Cited by 162
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Golde, T. E. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01201-2 · Cited by 119
The informed road map to prevention of Alzheimer Disease: a call to arms
McDade, E., Llibre-Guerra, J. J., Holtzman, D. M., Morris, J. C., & Bateman, R. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00467-y · Cited by 89
“targeting the amyloid pathway at different stages remains a viable strategy, and may be facilitated by next generation gamma secretase modulators [152, 153].”
BackgroundSecretases in Alzheimer's disease: Novel insights into proteolysis of APP and TREM2
Lichtenthaler, S. F., Tschirner, S. K., & Steiner, H. (2022) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2021.09.003 · Cited by 60
Turning the tide on Alzheimer’s disease: modulation of γ-secretase
Luo, J. E., & Li, Y.-M. (2022) · Cell & Bioscience · doi:10.1186/s13578-021-00738-7 · Cited by 59
“A collaboration between the University of California San Diego and Massachusetts General Hospital synthesized and characterized a series of pyridazine-derived GSM analogs [74].”
BackgroundImpact of increased APP gene dose in Down syndrome and the Dp16 mouse model
Sawa, M., Overk, C., Becker, A., Derse, D., Albay, R., Weldy, K., Salehi, A., Beach, T. G., Doran, E., Head, E., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12463 · Cited by 54
Self-citationAssociation of CSF Aβ 38 Levels With Risk of Alzheimer Disease–Related Decline
Cullen, N., Janelidze, S., Palmqvist, S., Stomrud, E., Mattsson, N., Hansson, O., & Initiative, A. D. N. (2021) · Neurology · doi:10.1212/wnl.0000000000013228 · Cited by 57
The advent of Alzheimer treatments will change the trajectory of human aging
Selkoe, D. J. (2024) · Nature Aging · doi:10.1038/s43587-024-00611-5 · Cited by 56
“Another GSM is being prepared for testing in a phase I trial 75 , and others are likely to follow.”
Conquering Alzheimer’s: a look at the therapies of the future
Abbott, A. (2023) · Nature · doi:10.1038/d41586-023-00954-w · Cited by 48
Gamma-secretase modulators: a promising route for the treatment of Alzheimer's disease
Nordvall, G., Lundkvist, J., & Sandin, J. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1279740 · Cited by 44
“Currently, only a limited number of GSM programs appear to be active, including UCSD-776890 from the group of Steven Wagner that received NIH funding for a Phase 1 study (Rynearson et al., 2021).”
BackgroundTesting the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease
Levin, J., Vöglein, J., Quiroz, Y. T., Bateman, R. J., Ghisays, V., Lopera, F., McDade, E., Reiman, E., Tariot, P. N., & Morris, J. C. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12624 · Cited by 40
The dense-core plaques of Alzheimer’s disease are granulomas
Lemke, G., & Huang, Y. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20212477 · Cited by 37
“Compounds that allosterically modulate, rather than inhibit, γ-secretase activity may represent promising new approaches to reducing Aβ peptide levels (Rynearson et al., 2021).”
BackgroundDe Strooper, B., & Karran, E. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00057-w · Cited by 36
“…in Table 2, these are potent compounds (low single-digit nanomolar range in cell culture experiments), which decrease plaque formation and improve behavior in preclinical models of AD (for example (Kounnas et al, 2010; Rynearson et al, 2021)), while some show little preclinical toxicity as well.”
BackgroundGuo, Y., Su, L., Liu, Q., Zhu, Y., Dai, Z., & Wang, Q. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.05.018 · Cited by 36
“strategies in many prokaryotes and eukaryotes [11-18].”
Volloch, V., & Rits‐Volloch, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512246 · Cited by 31
Amyloid fibril proteomics of AD brains reveals modifiers of aggregation and toxicity
Upadhyay, A., Chhangani, D., Rao, N. R., Kofler, J., Vassar, R. J., Rincón-Limas, D. E., & Savas, J. N. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00654-z · Cited by 30
“For example, a recent pharmacological study using pyridazine-based GSMs found reduced net production of Aβ42 and to a lesser degree Aβ40, while concomitantly enhancing production of Aβ38 and Aβ37 [47].”
BackgroundVersatile nanomaterials for Alzheimer’s disease: Pathogenesis inspired disease-modifying therapy
Xi, Y., Chen, Y., Jin, Y., Han, G., Song, M., Song, T., Shi, Y., Tao, L., Huang, Z., Zhou, J., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.034 · Cited by 27
Amyloid futures in the expanding pathology of brain aging and dementia
Thorwald, M. A., Silva, J. A., Head, E., & Finch, C. E. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12896 · Cited by 25
Liu, C., Guo, X., & Chang, X. (2022) · BioMed Research International · doi:10.1155/2022/4806163 · Cited by 24
“It is the dementia disease with the most extensive influence and the largest number of patients in the world [3].”
RetractedKang, K., Bai, J., Zhong, S., Zhang, R., Zhang, X., Xu, Y., Zhao, M., Zhao, C., & Zhou, Z. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/8169981 · Cited by 22
“Alzheimer ’ s disease (AD), an age-related and progressive neurodegenerative disorder in the elderly, is characterized by extracellular deposits of amyloid-beta (A β ) peptides and intracellular accumulation of hyperphosphorylated tau proteins [1].”
Bartesaghi, R., Vicari, S., & Mobley, W. C. (2022) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-041521-103641 · Cited by 21
Self-citationZhou, Z., Bai, J., Zhong, S., Zhang, R., Kang, K., Zhang, X., Xu, Y., Zhao, C., & Zhao, M. (2021) · The EPMA Journal · doi:10.1007/s13167-021-00261-2 · Cited by 20
“Alzheimer’s disease (AD) is the primary cause of dementia characterized by irreversible and progressive cognitive decline, along with behavioral and psychiatric alterations of differing extent [1, 2].”
BackgroundA case for seeking sex-specific treatments in Alzheimer’s disease
Lynch, M. A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1346621 · Cited by 20
Antony, D., Sheth, P., Swenson, A., Smoller, C., Maguire, K., & Grossberg, G. T. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2438317 · Cited by 19
Kim, J., Jeon, H., Kim, H. Y., & Kim, Y. S. (2023) · ChemBioChem · doi:10.1002/cbic.202300328 · Cited by 17
Vahid, Z. F., Eskandani, M., Dadashi, H., Vandghanooni, S., & Rashidi, M. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e40756 · Cited by 19
γ-Secretase: once and future drug target for Alzheimer’s disease
Wolfe, M. S. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2277350 · Cited by 16
“Nevertheless, a recent report showed promising preclinical validation for a new GSM [17], results that support an Investigational New Drug application to the FDA.”
ResultChen, X., Becker, A., Albay, R., Nguyen, P. D., Karachentsev, D., Roberts, A. J., Rynearson, K. D., Tanzi, R. E., & Mobley, W. C. (2024) · Annals of Neurology · doi:10.1002/ana.26958 · Cited by 16
Self-citationAdvances of therapy for Alzheimer's disease: An updated review
Mei, C., Zhan, J., Zhu, S., Zhang, Y., Xiong, C., Wang, J., Xu, Y. J., Zhong, H., & Cheng, J. (2024) · Brain‐X · doi:10.1002/brx2.68 · Cited by 16
Volloch, V., & Rits‐Volloch, S. (2022) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-220031 · Cited by 16
“This approach continues being developed, with some hopeful candidates appearing in recent studies [103, 104].”
BackgroundSmall molecules targeting γ-secretase and their potential biological applications
Wen, J., Liu, D., & Zhao, L. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114169 · Cited by 15
Recent advances in Alzheimer’s disease: From molecular mechanisms to therapeutic strategies
Rudman, M. D., Ulrich, J. D., & Holtzman, D. M. (2026) · Cell · doi:10.1016/j.cell.2026.06.006 · Cited by 18
Geerts, H., Bergeler, S., Walker, M., Rose, R. H., & van der Graaf, P. H. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12474 · Cited by 14
“…could in principle be expanded to also simulate the impact of novel amyloid therapies—many already in early clinical development—with different targets for instance focused solely on oligomers, 24 gamma-secretase modulators, 25 or with small molecules affecting the aggregation rate of A β species.”
BackgroundProbiotics/prebiotics/synbiotics and human neuropsychiatric outcomes: an umbrella review
Du, Q., Li, Q., Liu, C., Liao, G., Li, J., Yang, J., Zhang, Q., Gong, X., & Li, K. (2017) · Beneficial Microbes · doi:10.1163/18762891-bja00035 · Cited by 21
Chen, X., Sawa, M., Becker, A., Karachentsev, D., Zuo, X., Rynearson, K. D., Tanzi, R. E., & Mobley, W. C. (2023) · Annals of Neurology · doi:10.1002/ana.26659 · Cited by 13
“However, several clinical trials of these compounds demonstrated not only lack of efficacy but evidence of worsened cognition.41 As an alternative potentially useful therapeutic intervention, we envision a role for GSMs in modulating the cleavage of γ-secretase to reduce the levels of long Aβ peptides including Aβ42 a…”
BackgroundMethodInfluentialSelf-citationZhou, Z., Bai, J., Zhong, S., Zhang, R., Kang, K., Zhang, X., Xu, Y., Zhao, C., & Zhao, M. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/1260161 · Cited by 13
“Alzheimer ’ s disease (AD), referring to an irreversible neuro-degenerative disorder, is manifested in cognitive decline, along with behavioral and psychiatric abnormalities of varying extent [1, 2].”
Pettersson, M., Johnson, D. S., Humphrey, J. M., Ende, C. W. A., Butler, T. W., Dorff, P. H., Efremov, I. V., Evrard, E., Green, M., Helal, C. J., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00580 · Cited by 11
Characterizing the Chemical Space of γ-Secretase Inhibitors and Modulators
Santiago, Á., Guzmán‐Ocampo, D. C., Aguayo‐Ortiz, R., & Domínguez, L. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00313 · Cited by 10
Targeting the awry Aβ pathway in Alzheimer’s disease: hype and hurdles
Al-Kuraishy, H. M., Sulaiman, G. M., Al-Gareeb, A. I., Mohammed, H. A., Albuhadily, A. K., & Abomughaid, M. M. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01983-9 · Cited by 8
“Finally, natural product-derived γ-secretase modulators such as NIC5-15, RO5506284, and UCSD-776890 have potential therapeutic efficacy against amyloid burden in animal model studies (Brendel et al. 2015; Xu et al. 2020; Rynearson et al. 2021).”
The Neuroprotective Effect of Rooibos Herbal Tea Against Alzheimer's Disease: A Review
Chipofya, E., Docrat, T. F., & Marnewick, J. L. (2024) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202400670 · Cited by 8
Targeting γ-secretase for familial Alzheimer’s disease
Wolfe, M. S. (2021) · Medicinal Chemistry Research · doi:10.1007/s00044-021-02744-3 · Cited by 8
Raza, M. A., Folz, A., Victorino, D. B., Xing, Z., Chen, X., Zuo, X., Borden, L. K., Potier, M., Mobley, W. C., Dierssen, M., et al. (2026) · STAR Protocols · doi:10.1016/j.xpro.2026.104717 · Cited by 7
“226–229 In Ts65Dn mice, BPN-15606 reduced toxic A β 42 and A β 40 without altering total APP and ameliorated AD-related pathology.”
Self-citationZhao, Y., Singh, K., Karuturi, R. C., Hefny, A. A., Shakeri, A., Beazely, M. A., & Rao, P. P. N. (2024) · ChemMedChem · doi:10.1002/cmdc.202400198 · Cited by 7
Air pollution amyloidogenesis is attenuated by the gamma‐secretase modulator GSM‐15606
Godoy-Lugo, J. A., Thorwald, M. A., Cacciottolo, M., D’Agostino, C., Chakhoyan, A., Sioutas, C., Tanzi, R. E., Rynearson, K. D., & Finch, C. E. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14086 · Cited by 6
“17 Brain imaging (e.g., positron emission tomography imaging for tracking of radiolabeled GSMs 43 ) may further identify brain regions affected by AirPoll to investigate protective effects of GSMs and other treatments.”
BackgroundInfluentialSelf-citationThe manipulator behind “Scissors”: γ -secretase and its modulators in Alzheimer’s disease
Ning, G., Fan, X., Du, J., wenxue, Z., Sijia, W., Meinei, C., Xiaolong, D., & Yiming, Q. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1637671 · Cited by 5
The Janus face of CaMKII: from memory consolidation to neurotoxic switch in Alzheimer’s disease
Tang, L., Liu, F., Sun, X., Yang, J., Liu, Y., Pan, X., Hao, L., Lou, F., & Su, J. (2025) · Archives of Toxicology · doi:10.1007/s00204-025-04160-7 · Cited by 6
“Recently, a novel pyridazine-containing γ-secretase modulator (BPN-15606) and its analogs (UCSD-776890 and UCSD-779690) have demonstrated acceptable safety and therapeutic potential, though further clinical studies are still warranted (Rynearson et al. 2021).”
Boeuf, W. L., Hefny, A. A., Karuturi, R. C., & Rao, P. P. N. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00760 · Cited by 5
Bhattarai, S., Devkota, S., & Wolfe, M. S. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01395 · Cited by 5
Ohno, M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231451 · Cited by 5
A promising new γ-secretase modulator for Alzheimer’s disease
Zakaria, J. A. D., & Vassar, R. J. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20210077 · Cited by 4
Down syndrome: a model for chromosome abnormalities
Overk, C., & Mobley, W. C. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00007-1 · Cited by 4
Self-citationVolloch, V., & Rits‐Volloch, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094252 · Cited by 3
Current and emerging therapeutic approaches in Alzheimer’s disease
Chauhan, A., Devi, R., Singh, S., Thakur, R., Bhutani, K., Sharma, R., Kumari, A., Kumar, H., Pal, S., & Saini, A. K. (2026) · Discover Neuroscience · doi:10.1186/s13064-026-00290-5 · Cited by 3
“GSMs/GSSs were developed to lower the levels of toxic Aβ42 while sparing Notch signaling by shifting γ-secretase activity towards shorter, less aggregation-prone peptides such as Aβ38 [84, 85].”
Zhang, C. M., Inamdar, S. M., Swaminathan, S., Marenda, D. R., & Saunders, A. J. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.821059 · Cited by 3
Self-citationComputer-aided Drug Design for Alzheimer's Disease: Recent Advancements and Future Perspectives
Rohilla, S., & Goyal, G. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266343814250713100224 · Cited by 2
Increase of brain Aβ peptides and secretase activity during normal aging in rodent and human
Godoy-Lugo, J. A., Thorwald, M. A., Head, E., Gomm, A., Zhang, C., Tanzi, R. E., & Finch, C. E. (2025) · GeroScience · doi:10.1007/s11357-025-01926-w · Cited by 2
“Hence, clinical interventions to diminish amyloid pools could consider inhibitors of the secretases that produce soluble Aβ peptides [31, 32].”
Self-citationNetzer, W. J., Sinha, A., Ghias, M. H., Chang, E., Gindinova, K., Mui, E., Seo, J.-S., & Sinha, S. C. (2024) · Frontiers in Chemistry · doi:10.3389/fchem.2024.1381205 · Cited by 2
APP Gene-based Strategies to Combat Alzheimer's Disease in Down Syndrome
Chen, X. (2025) · Current Genomics · doi:10.2174/0113892029360836250127103637 · Cited by 2
Ahmad, H. A., Zafar, M., Khan, T., & Khan, M. I. (2026) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-026-05505-1 · Cited by 2
“Thus far, no GSM has reached Phase II efficacy trials in AD patients , but the approach remains enticing for its potential to prevent amyloid buildup with fewer side effects [54 ].”
The γ-secretase complex: from discovery to a therapeutic target
Malvankar, S. R., & Wolfe, M. S. (2026) · RSC Chemical Biology · doi:10.1039/d6cb00022c · Cited by 1
Fotio, Y., Masri, S. A., Shi, Z., Le, J., Das, S., Rubtsova, V. I., Tagne, A. M., Jang, C., Swarup, V., & Piomelli, D. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.aea8738 · Cited by 1
Hug, B., Tanzi, R. E., & Wagner, S. L. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108975759.009
Self-citationUpadhyay, A., Chhangani, D., Rao, N. R., Kofler, J., Vassar, R. J., Rincón-Limas, D. E., & Savas, J. N. (2023) · Figshare · doi:10.6084/m9.figshare.24144129
Upadhyay, A., Chhangani, D., Rao, N. R., Kofler, J., Vassar, R. J., Rincón-Limas, D. E., & Savas, J. N. (2023) · Figshare · doi:10.6084/m9.figshare.24144138
Upadhyay, A., Chhangani, D., Rao, N. R., Kofler, J., Vassar, R. J., Rincón-Limas, D. E., & Savas, J. N. (2023) · Figshare · doi:10.6084/m9.figshare.24144147
Upadhyay, A., Chhangani, D., Rao, N. R., Kofler, J., Vassar, R. J., Rincón-Limas, D. E., & Savas, J. N. (2023) · Figshare · doi:10.6084/m9.figshare.24144132
Upadhyay, A., Chhangani, D., Rao, N. R., Kofler, J., Vassar, R. J., Rincón-Limas, D. E., & Savas, J. N. (2023) · Figshare · doi:10.6084/m9.figshare.24144135
Upadhyay, A., Chhangani, D., Rao, N. R., Kofler, J., Vassar, R. J., Rincón-Limas, D. E., & Savas, J. N. (2023) · Figshare · doi:10.6084/m9.figshare.24144144
Upadhyay, A., Chhangani, D., Rao, N. R., Kofler, J., Vassar, R. J., Rincón-Limas, D. E., & Savas, J. N. (2023) · Figshare · doi:10.6084/m9.figshare.24144141
Chen, X. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00918
“or DS mouse models, as well as in nonhuman primates (Wagner et al., 2017; Prikhodko et al., 2020; Rynearson et al., 2021; Chen et al., 2024).”
γ-Secretase in the pathogenesis of Alzheimer’s disease and therapeutic potential of its modulators
Николаевич, В. В., Иванович, В. В., & Shabanov, P. D. (2024) · Психофармакология и биологическая наркология · doi:10.17816/phbn635851
Upadhyay, A., Chhangani, D., Rao, N. R., Kofler, J., Vassar, R. J., Rincon-Limas, D. E., & Savas, J. N. (2023) · Figshare · doi:10.6084/m9.figshare.24144123
Upadhyay, A., Chhangani, D., Rao, N. R., Kofler, J., Vassar, R. J., Rincon-Limas, D. E., & Savas, J. N. (2023) · Figshare · doi:10.6084/m9.figshare.24144120
Huang, X. (2024) · IUScholarWorks (Indiana University) · doi:10.7912/zjrk-jj82
Shariq, M., Pan, W., Chen, X., Xiang, W., Lugo, J. G., Peng, L., Levi, J. N., Ibreyeva, A., Shkirkova, K., Nguyen, W., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.27.702094
Fotio, Y., Masri, S. A., Shi, Z., Le, J., Das, S., Rubtsova, V. I., Tagne, A. M., Jang, C., Swarup, V., & Piomelli, D. (2026) · Journal of Pain · doi:10.1016/j.jpain.2025.105682
Drug Discovery for Alzheimer’s Disease: Current Status
Wolfe, M. S. (2026) · Topics in medicinal chemistry · doi:10.1007/7355_2026_186
Ismeurt, C. (2021) · theses.fr (ABES) · doi:10.70675/159d4638zb5f8z4580zb26fzd0419dba4d37 · Cited by 1
Recent Advances in the Development of γ-Secretase Modulators to Treat Alzheimer’s Disease
Johnson, D. S., Pettersson, M., Liu, C., Mekala, S., & Li, Y. (2026) · Topics in medicinal chemistry · doi:10.1007/7355_2026_187
Yuan, Y., Xing, S., Ren, P., Chen, Z., & Fu, Y. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261497298
BindingDB (2023) · UC San Diego · doi:10.7270/q2hd80pd
Sarmiento, R. M. R., Ratni, H., Reutlinger, M., Pichereau, S., Vifian, W., Gerlach, I., Lindemann, L., & Baumann, K. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01762
Metadata
- Authors
- Rynearson, K. D., Ponnusamy, M., Prikhodko, O., Xie, Y., Zhang, C., Nguyen, P., Hug, B., Sawa, M., Becker, A., Spencer, B., Florio, J., Mante, M., Salehi, B., Arias, C., Galasko, D., Head, B. P., Johnson, G., Lin, J. H., Duddy, S. K., Rissman, R. A., Mobley, W. C., Thinakaran, G., Tanzi, R. E., & Wagner, S. L.
- Affiliations
- University of California San Diego (US)
- University of South Florida (US)
- Massachusetts General Hospital (US)
- Veterans Health Administration (US)
- NuPharmAdvise, Sanbornton, NH 6
- Seven (CZ)
- Integrated Nonclinical Development Solutions (United States) (US)
- Corresponding author
- Wagner, Steven L.
- ORCID
- Rynearson, Kevin D.
- Ponnusamy, Moorthi
- Prikhodko, Olga
- Xie, Yuhuan
- Zhang, Can
- Nguyen, Phuong
- Hug, Brenda
- Sawa, Mariko
- Becker, Ann
- Spencer, Brian
- Florio, Jazmin
- Mante, Michael
- Salehi, Bahar
- Arias, Carlos
- Galasko, Douglas
- Head, Brian P.
- Johnson, Graham
- Lin, Jiunn H.
- Duddy, Steven K.
- Rissman, Robert A.
- Mobley, William C.
- Thinakaran, Gopal
- Tanzi, Rudolph E.
- Wagner, Steven L.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2021-03-02
- Volume
- 218
- Issue
- 4
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC7931646
- OpenAlex
- W3135208068
- Cited by
- 76
- References
- 46
- Citations by year
- 2026: 11 · 2025: 8 · 2024: 17 · 2023: 11 · 2022: 17 · 2021: 11
- FWCI
- 10.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-sa)
- Funders
- Cure Alzheimer’s Fund
- National Institute of Neurological Disorders and Stroke
- National Institute on Aging (NS 074501, U01AG048986, R01AG055523, R01AG054223, R01AG056061)
- National Institutes of Health
- Chen Foundation (R-86U55A)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- γ-secretase modulators, Alzheimer's disease prevention, early-onset familial Alzheimer's disease, amyloid-beta 42, gamma-secretase inhibitors, allosteric modulation, transgenic mouse model, preclinical safety, dose-dependent efficacy, primary prevention
- MeSH terms
- Alzheimer Disease, Animals, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Female, Humans, Macaca fascicularis, Male, Mice, Inbred C57BL, Mice, Transgenic, Neuroblastoma, Peptide Fragments, Phenethylamines, Pyridazines, Signal Transduction, Amyloid beta-Peptides, Treatment Outcome, Rats, Sprague-Dawley, Cell Line, Tumor, Mice, Rats, Amyloid Precursor Protein Secretases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.